Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.

  • Revenue in EUR (TTM)7.37bn
  • Net income in EUR195.23m
  • Incorporated1987
  • Employees23.83k
  • Location
    Grifols SAParque Empresarial Can Sant JoanAvinguda de la Generalitat, 152-158SANT CUGAT DEL VALLES 08174SpainESP
  • Phone+34 935710000
  • Fax+34 935710267
  • Websitehttps://www.grifols.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GRF:MCE since
announced
Transaction
value
Immunotek Biocenters LLC-Plasma Centers(6)Deal completed01 Mar 202501 Mar 2025Deal completed9.56%62.42m
Data delayed at least 15 minutes, as of Jul 15 2025 16:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
WuXi XDC Cayman Inc484.64m127.92m6.33bn2.04k52.967.9544.8013.050.90910.90913.446.060.511033.993.242,174,251.0013.49--17.66--30.60--26.40--2.43--0.0696--90.80--277.24------
Elanco Animal Health Inc3.80bn319.77m6.34bn9.00k19.901.167.181.670.74830.74838.9212.800.32841.244.52491,888.902.77-2.713.05-3.0254.8954.728.43-9.521.461.140.4089--0.49817.65127.4637.85-3.99--
Krka dd Novo Mesto1.95bn410.29m6.54bn12.93k14.942.5313.053.3613.3513.3563.2978.700.65361.293.31151,874.5013.7712.8016.4715.3157.4857.3921.0719.112.69--0.005859.405.715.0413.717.770.840414.19
Aurobindo Pharma Ltd3.16bn347.43m6.59bn8.80k19.042.0312.882.0859.8159.81544.32562.210.66891.286.01--7.348.6210.2512.1358.9454.5110.9812.381.139.690.202--9.396.559.864.1511.98--
Corcept Therapeutics Inc587.63m114.87m6.62bn500.0062.5411.2956.8811.261.161.165.916.450.91250.997311.121,370,892.0017.8420.0721.2323.0198.4398.5319.5524.892.96--0.000.0039.9417.1133.048.4414.83--
Eisai Co Ltd4.58bn269.48m6.70bn13.51k24.161.3313.121.46163.81163.812,784.172,982.520.56780.86444.4758,448,100.003.463.814.685.1478.6277.466.096.441.37--0.17898.016.422.569.49-17.54-14.480.00
Roivant Sciences Ltd24.91m-467.24m6.78bn750.00--1.73--272.13-0.7559-0.24080.046.740.0046----38,737.33-11.535.89-12.966.9896.8690.39-2,511.84639.97----0.000.00-11.19-15.56-111.69---1.32--
Grifols SA7.37bn195.23m7.18bn23.83k40.831.419.900.97370.28530.285310.608.290.34351.267.24309,339.401.321.721.722.2138.7738.853.845.430.97472.040.5478--9.417.18270.81-24.15-2.07--
Abbott India Ltd638.78m140.97m7.26bn3.81k51.5217.2249.0311.37665.62665.623,016.081,992.141.154.6117.65--25.4622.4233.8330.4245.4444.7022.0718.832.76141.980.044455.919.589.3817.7518.9927.3134.73
3SBio Inc1.09bn249.99m7.39bn5.58k30.363.9323.656.780.92880.92884.047.180.38081.638.031,788,423.009.277.9513.2110.3285.9583.7324.3522.681.57--0.1646--16.5311.3634.9316.5114.65--
Shanghai Fosun Pharmaceutical (Group)4.82bn349.86m7.53bn40.56k23.371.43--1.561.101.1015.1517.940.34813.055.18994,409.403.173.905.306.4946.6348.819.099.850.7779--0.37732.08-0.80287.5216.08-3.572.17-3.88
Kyowa Kirin Co Ltd2.87bn298.34m7.55bn5.67k25.431.5616.972.6397.3497.34939.971,588.590.47451.783.9287,266,360.004.936.375.757.2573.4075.1310.3914.652.7117.520.0046.3812.0610.14-26.269.7137.716.67
BridgeBio Pharma Inc109.23m-572.65m7.76bn725.00------71.07-3.53-3.530.6744-8.680.1472----175,744.80-78.20-75.74-95.66-94.2495.3596.67-531.17-716.924.54-4.693.32--2,285.2740.4816.70--11.63--
Data as of Jul 15 2025. Currency figures normalised to Grifols SA's reporting currency: Euro EUR

Institutional shareholders

21.96%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 05 Feb 202514.51m3.41%
DWS Investment GmbHas of 10 Jun 202413.78m3.23%
Flat Footed LLCas of 31 Dec 202413.34m3.13%
The Vanguard Group, Inc.as of 31 May 20259.40m2.21%
Mason Capital Management LLCas of 31 Dec 20249.01m2.11%
BNP Paribas Asset Management Europe SASas of 13 Mar 20248.38m1.97%
BlackRock Fund Advisorsas of 03 Jul 20257.57m1.78%
Bestinver Gesti�n SA SGIICas of 31 Dec 20246.58m1.55%
Norges Bank Investment Managementas of 31 Dec 20246.17m1.45%
Rokos Capital Management LLPas of 31 Dec 20244.84m1.14%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.